Newsroom 2005

2005 Releases

Cervical Cancer Vaccine Submitted for Regulatory Approval in Australia
CSL Limited announced today that the cervical cancer vaccine GARDASIL® (Quadrivalent Human Papillomavirus Types 6, 11, 16, 18 Recombinant Vaccine) was one step closer to being made available to Australians, after being submitted today for regulatory review to the Therapeutic Goods Administration (TGA). An application requesting priority review of GARDASIL has also been submitted to the TGA. More.

CSL Announces Application for Licensure of Gardasil® by Merck & Co., Inc.
CSL Limited announced today that its licensee, Merck & Co., Inc., has submitted a Biologics License Application (BLA) for GARDASIL (quadrivalent human papillomavirus types 6, 11, 16, 18, recombinant vaccine) to the U.S. Food and Drug Administration (FDA) on December 1, 2005. More.

Investigational Vaccine Prevents 100% High Grade Cervical Pre-Cancers, and Non-Invasive Cervical Cancers in Phase III Study
CSL Limited announced today that GARDASIL™, an investigational vaccine developed by Merck & Co., Inc., based on technology licensed from CSL, prevented 100 percent of high-grade cervical pre-cancers and non-invasive cervical cancers (CIN 2/3 and AIS) associated with human papillomavirus (HPV) types 16 and 18 which account for 70 percent of all cervical cancers. More.

CSL Announces 2005 Full Year Results
CSL today announced its operational results for the full year ended 30 June 2005. More.

CSL Limited enters into License and Option Agreement with Merck Co. Inc. for its Iscomatrix® Adjuvant Technology
CSL Limited, Australia’s leading biopharmaceutical company, today announced that it has signed a license and option agreement with Merck & Co. Inc., of Whitehouse Station, New Jersey, USA, granting certain rights and options to Merck in a number of fields for the use of CSL’s ISCOMATRIX® adjuvant in Merck’s pipeline of investigational vaccine products. More.

Further Share Buyback Announced
CSL Limited today announced its intention to conduct a further on-market buyback of up to 8 million shares. More.

CSL Completes Sale of JRH Biosciences
CSL Limited announced today that it has completed the sale of its JRH Biosciences Division (JRH) to Sigma-Aldrich Corporation for US$370m cash subject to normal closing adjustments. More.

CSL Reports $160M First Half Result
CSL Limited today announced its first half result for period ended 31 December 2004. More.

CSL and BAYER Healthcare Agreement to provide Recombinant FACTOR VIII for Australians living with Haemophilia A
CSL Limited, Australia’s national fractionator of plasma therapeutics since 1952, and Bayer HealthCare - Australia, today announced an agreement, with an initial 5 year term, granting CSL Limited’s Bioplasma Division exclusive distribution rights to KOGENATE®FS in Australia. KOGENATE®FS is a leading recombinant Factor VIII used in the treatment of Haemophilia A, and manufactured using advanced recombinant DNA technology. More.

CSL Limited and Merck & Co, Inc Enter Into Cross-License and Settlement Arrangement with GlaxoSmithKline For HPV Vaccine Patents
CSL today announced a cross-license and settlement arrangement between CSL, Merck & Co Inc, (Merck) and GlaxoSmithKline (GSK) regarding certain patents related to the human papillomavirus (HPV) vaccine. More.

CSL Enters Agreement to Sell JRH
CSL Limited announced today that it has entered into an agreement with Sigma-Aldrich Corporation for the sale of its cell culture reagent business, JRH Biosciences (JRH) for US$370m (A$492m) subject to normal purchase conditions and adjustments which compares with a book value of A$137m as at 30 June 2004. More.

© 2017 CSL Limited